Moreover, previously underappreciated hyperinflammatory syndromes, including hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS) or immune-related adverse events, have recently gained attention since anti-inflammatory therapy targeting specific cytokines such as interleukin-6 (IL-6) and IL-1 is effective in treating these otherwise often lethal conditions [2,3]. This evidence concerns the gene IL1B and hemophagocytic syndrome.